iVeena submits IND to FDA for a phase 2 clinical trial for pediatric myopia
Published on June 4, 2025
IVMED-85 is a preservative-free, non-atropine daily drop that slows myopia progression by strengthening scleral and corneal collagen crosslinks via LOX activation.